下載本文檔
版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEThiomyristoylCat. No.: HY-101278CAS No.: 1429749-41-6分式: CHNOS分量: 581.85作靶點(diǎn): Sirtuin作通路: Cell Cycle/DNA Damage; Epigenetics儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 32 mg/mL (55.00 mM
2、)* means soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 1.7187 mL 8.5933 mL 17.1866 mL5 mM 0.3437 mL 1.7187 mL 3.4373 mL10 mM 0.1719 mL 0.8593 mL 1.7187 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍?,配制前?qǐng)先配制澄清的儲(chǔ)備液,再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性,體內(nèi)實(shí)
3、驗(yàn)的作液,建議您現(xiàn)現(xiàn)配,當(dāng)天使;澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;以下溶劑前的百分 指該溶劑在您配制終溶液中的體積占):1. 請(qǐng)依序添加每種溶劑: 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (4.30 mM); Clear solution2. 請(qǐng)依序添加每種溶劑: 10% DMSO 90% corn oilSolubility: 2.5 mg/mL (4.30 mM); Clear solution1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEBIO
4、LOGICAL ACTIVITY物活性 Thiomyristoyl效特異性的SIRT2抑制劑,IC50值為28 nM。IC50 & Target SIRT2 SIRT128 nM (IC50) 98 M (IC50)體外研究 Thiomyristoyl (TM) is a potent SIRT2-specific inhibitor with broad anticancer activity but little effect on non-cancerous cells. SIRT2-inhibition promotes c-Myc ubiquitination and degrada
5、tion, suggesting the therapeuticpotential of TM to target certain c-Myc-driven cancers. TM could inhibit SIRT2 with an IC50 of 28 nM, butinhibits SIRT1 with an IC50 value of 98 M and does not inhibit SIRT3 even at 200 M. TM inhibits threehuman breast cancer cell lines, MCF-7, MDA-MB-468, and MDA-MB-
6、231 1.體內(nèi)研究 TM inhibits tumor growth in mouse models of breast cancer. TM does not cause significant toxicity in miceand no significant weight loss is observed in TM-treated mice. S5H, the acetyl-a-tubulin level is moderatelybut statistically significantly increased in tumors from TM-treated mice com
7、pared with those from vehicle-treated mice, suggesting that TM indeed inhibits SIRT2 in vivo 1.PROTOCOLCell Assay 1 Cells are seeded into 96-well plates at 3,0004,000 cells per well. After 24 hr, test compounds(Thiomyristoyl) are added to cells to final concentrations ranging from 1 to 50 M. Cells a
8、re then incubatedfor 72 hr and cell viability is measured using the CellTiter-Blue viability assay. Relative cell viability in thepresence of test compounds is normalized to the vehicle-treated controls after background subtraction.GraphPad Prism software is used to determine the IC50 values. Knockd
9、own of SIRT1-7 in various cell linesis achieved by lentiviral infection 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Neoplasia. 2019 Mar 29;21(5):429-441.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Jing H, et al. A SIRT2-Selective Inhibitor Promotes c-Myc Oncoprotein Degradation and Exhibits Broad Anticancer Activity. Cancer Cell.2016 Mar 14;29(3):297-310.McePdfHeightCaution: Product has not been fully validated f
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 2025 小學(xué)二年級(jí)道德與法治上冊(cè)友好合作共同完成繪畫(huà)課件
- 2026年中醫(yī)藥專(zhuān)業(yè)知識(shí)水平測(cè)試模擬題
- 2026年職業(yè)培訓(xùn)與認(rèn)證類(lèi)試題
- 2026年計(jì)算機(jī)視覺(jué)專(zhuān)業(yè)測(cè)試題圖像識(shí)別技術(shù)發(fā)展趨勢(shì)分析
- 宦怡肝硬化課件
- 天天練課件二維碼
- 2026年桐城師范高等專(zhuān)科學(xué)校單招綜合素質(zhì)筆試備考題庫(kù)含詳細(xì)答案解析
- 2026年科爾沁藝術(shù)職業(yè)學(xué)院?jiǎn)握芯C合素質(zhì)考試參考題庫(kù)含詳細(xì)答案解析
- 2026年山東水利職業(yè)學(xué)院?jiǎn)握芯C合素質(zhì)筆試備考題庫(kù)含詳細(xì)答案解析
- 2026年西安鐵路職業(yè)技術(shù)學(xué)院?jiǎn)握新殬I(yè)技能考試備考試題含詳細(xì)答案解析
- (2025)事業(yè)單位考試(面試)試題與答案
- CNAS-GC25-2023 服務(wù)認(rèn)證機(jī)構(gòu)認(rèn)證業(yè)務(wù)范圍及能力管理實(shí)施指南
- 入伍智力測(cè)試題及答案
- 竣工驗(yàn)收方案模板
- 企業(yè)安全生產(chǎn)內(nèi)業(yè)資料全套范本
- 安全生產(chǎn)標(biāo)準(zhǔn)化與安全文化建設(shè)的關(guān)系
- DL-T5054-2016火力發(fā)電廠汽水管道設(shè)計(jì)規(guī)范
- 耳部刮痧治療
- 神經(jīng)外科介入神經(jīng)放射治療技術(shù)操作規(guī)范2023版
- 多模態(tài)數(shù)據(jù)的聯(lián)合增強(qiáng)技術(shù)
- 濱海事業(yè)單位招聘2023年考試真題及答案解析1
評(píng)論
0/150
提交評(píng)論